Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 9/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13753537 | 1.00 | AKR1C3 (0.62) | AKR1C3HRH4HRH3POLBSMN1; SMN2 | |
| SCHEMBL15533406 | 0.84 | AKR1C3 (0.62) | AKR1C3HRH4HRH3POLBSMN1; SMN2 | |
| SCHEMBL24235367 | 0.83 | AKR1C3 (0.61) | AKR1C3HRH4HRH3POLBSMN1; SMN2 | |
| SCHEMBL30310614 | 0.82 | AKR1C3 (0.60) | AKR1C3HRH4HRH3POLBSMN1; SMN2 | |
| SCHEMBL13201971 | 0.82 | AKR1C3 (0.63) | AKR1C3HRH4HRH3POLBSMN1; SMN2 | |
| SCHEMBL22615151 | 0.82 | HRH4 (0.58) | AKR1C3HRH4HRH3POLBSMN1; SMN2 | |
| SCHEMBL22615187 | 0.82 | HRH4 (0.58) | AKR1C3HRH4HRH3POLBSMN1; SMN2 | |
| SCHEMBL22615152 | 0.82 | HRH4 (0.58) | AKR1C3HRH4HRH3POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6823552 | 0.80 | AKR1C3 (0.57) | AKR1C3HRH4HRH3POLBSMN1; SMN2 | |
| SCHEMBL19360634 | 0.80 | HRH4 (0.58) | AKR1C3HRH4HRH3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815863-B2 | Hydrogen bond forming fluoro ketolides for treating diseases | CEMPRA PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Q6ZSR9, LSS, LCT | AKR1C3 104/4885HRH4 3514/4885HRH3 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.